/ 2 items

#TEVA↓

CORT/ 02/19/2026 · 10:51 AM

Corcept Therapeutics Stock Drops After Losing Patent Appeal to Teva

Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.

TEVA/ 11/05/2025 · 8:18 AM

Teva Pharmaceuticals Beats Q3 Expectations as Branded Drug Strategy Pays Off

Teva Pharmaceuticals (TEVA) Q3 2025 earnings beat expectations with 33% growth in branded drugs led by Austedo. Stock surges 12% as innovative portfolio drives transformation.